New targets and inhibitors of HBV replication to combat drug resistance.
All the approved chemotherapeutic drugs for the treatment of HBV hepatitis are nucleoside analogs targeting on HBV DNA polymerase. Drugs targeting on other viral unique targets are needed. A new class of chemicals with novel action against HBV replication was discovered. A brief description of their mode of action is given.
Cheng
Yung-Chi
YC
Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, SHM B254, New Haven, CT 06510, USA. yccheng@yale.edu
Ying
Chun-Xiao
CX
Leung
Chung-Hang
CH
Li
Ying
Y
D000998:Antiviral Agents / Q000138:chemical synthesis / Q000494:pharmacology; D004279:DNA, Viral / Q000096:biosynthesis; D015195:Drug Design; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D017705:Lignans; D008826:Microbial Sensitivity Tests; D019384:Nucleic Acid Synthesis Inhibitors; D014779:Virus Replication / Q000187:drug effects*; D014970:Xanthines / Q000494:pharmacology
D000998:Antiviral Agents; D004279:DNA, Viral; D017705:Lignans; D019384:Nucleic Acid Synthesis Inhibitors; D014970:Xanthines; C505802:helioxanthin